MedPath

Prospective Study of Thoracolumbar Spinal Fusion Graft

Not Applicable
Active, not recruiting
Conditions
Lumbar Degenerative Disc Disease
Registration Number
NCT02297256
Lead Sponsor
NYU Langone Health
Brief Summary

This study is a single-center, prospective randomized clinical study intended to compare and evaluate the efficacy of subjects who are treated with bone marrow aspirate concentrate (BMAC) and allograft to iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.

Detailed Description

Subjects who are candidates for posterior lumbar or lumbosacral spinal fusion without anterior interbody support will be screened for inclusion in the study. Participants will be enrolled and randomized to either the BMAC + allograft or ICBG group. An enrollment ratio of two BMAC + allograft to one ICBG subject (2:1) for up to a total of 40 subjects will be enrolled in the study which also accounts for failed screening subjects. The study will determine and compare differences in fusion rate and health related quality of life parameters at 6 weeks, 3 months, 6 months, 1 year, and 2 years postoperatively.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
17
Inclusion Criteria
  • Must be 18 years old or older
  • Scheduled for elective posterior spinal fusion of the thoracolumbar spine or lumbar spine with or without anterior interbody support
  • Failed at least 6 weeks of conservative care
  • ODI v2.1 score > 30%
  • No contraindication to BMAC (as per manufacturer)
  • Signed consent form
Exclusion Criteria
  • Spondylolisthesis grade ≥ 3
  • Pagets disease, osteomalacia, or any metabolic bone disease
  • Use of medications that interfere with bone healing (chronic steroids)
  • Patient unlikely to comply with post-op schedule with physician
  • Recent history of chemical dependency
  • Participation in other investigational device trial(s) within past 30 days
  • Active malignancy
  • Pregnancy or planning to become pregnant
  • Direct involvement in execution of this protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
CT scan to assess fusion statusPre-operative, Post Operative 1 Year
Oswestry Disability Index (ODI)Pre-operative, Post Operative 1 Year
Short Form Health Survey (SF-12)Pre-op, Post Operative 1 Year
Length of StayPost Operative 1 Year
Numeric Pain Rating ScalePre-op, Post Operative 1 Year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

NYU Hospital for Joint Diseases

🇺🇸

New York, New York, United States

Center for Musculoskeletal Care (CMC)

🇺🇸

New York, New York, United States

NY Spine Institute

🇺🇸

Westbury, New York, United States

NYU Hospital for Joint Diseases
🇺🇸New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath